Stockscreener 앱 받기
13.35
4.23%
-0.59
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Is Zevra’s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)? - Sahm
Zevra Therapeutics (ZVRA) Q4 2024 earnings summary - Quartr
Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com - Investing.com India
[144] ZEVRA THERAPEUTICS, INC. SEC Filing - Stock Titan
Zevra Therapeutics (ZVRA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary - Quartr
Zevra Therapeutics (ZVRA) Surges 3.11%: Support and Resistance Levels in FocusStandard Deviation - dars.gov.et
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively? - Sahm
ZVRAZevra Therapeutics Inc Dividends - Finviz
(ZVRA) Risk Channels and Responsive Allocation - Stock Traders Daily
Enterprise value to revenue forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value Benchmark - marketscreener.com
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index - marketscreener.com
ZVRA Q1 2026 Earnings: Earnings Per Share Surges Past Estimates with 118% SurpriseNew Analyst Coverage - dars.gov.et
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index - marketscreener.com
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to book forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Price to sales forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Enterprise value to EBIT forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Price to earnings forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. – DUS:1GDA - TradingView
Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Defensive Index - marketscreener.com
Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA) - TradingView
Zevra Therapeutics, Inc. Actuals & Estimates (DUS:1GDA) - TradingView
1GDA Forecast — Price Target — Prediction for 2027 - TradingView
Zevra Therapeutics publishes phase 2 3 study on arimoclomol for Niemann-Pick disease type C in infants - Traders Union
ZVRA Forecast — Price Target — Prediction for 2027 - TradingView
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating - Moomoo
H.C. Wainwright reiterates Zevra Therapeutics stock rating on infant study data - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) - Sahm
Zevra Therapeutics chief legal & compliance sells $438,303 in stock By Investing.com - Investing.com South Africa
Form 4 Zevra Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
ZVRA: Zevra Therapeutics Releases Positive Findings on Arimoclom - GuruFocus
Zevra Therapeutics chief legal & compliance sells $438,303 in stock - Investing.com
Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise - Stock Titan
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Zevra Therapeutics reports positive MIPLYFFA pediatric data - grafa.com
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Zevra Therapeutics Announces Publication of Positive - GlobeNewswire
(ZVRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options - Benzinga
Corey M. Watton Seizes Opportunity: Acquires $51K Worth Of Zevra Therapeutics Stock Options - Benzinga
Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options - Stock Titan
Zevra Therapeutics (ZVRA) director awarded 30,000 options at $11.17 strike - Stock Titan
Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) awards director 30,000 stock options - Stock Titan
Zevra Therapeutics (NASDAQ: ZVRA) director gets 30,000 stock options grant - Stock Titan
Zevra Therapeutics (ZVRA) director awarded 30,000 stock options at set price - Stock Titan
Zevra Therapeutics Inc (ZVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zevra Therapeutics Inc (ZVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zevra Therapeutics Inc (ZVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
2.64%
자본화:
|
볼륨(24시간):